SAN DIEGO, CA, May 27, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today the appointment of David L. Linemeyer, Ph.D., to the position of Vice President, Biology.
Dr. Linemeyer has more than 20 years of experience in directing biology research programs and collaborative research projects in the biotechnology and pharmaceutical industries. His expertise includes the characterization of novel receptors and the establishment of receptor-based assays similar to the technologies used by Senomyx to discover new flavor ingredients. He is an inventor on numerous patents and is a co-author of approximately 50 scientific publications. Dr. Linemeyer will be joining Senomyx's strong scientific management team that includes Mark J. Zoller, Ph.D., Executive Vice President of Discovery & Development and Chief Scientific Officer, and Donald S. Karanewsky, Ph.D., Senior Vice President, Discovery.
"In addition to leading research departments that focused on cell biology and the discovery of new agents, David has extensive experience in intellectual property, regulatory affairs, and business development activities at both large and small companies," noted Kent Snyder, President and Chief Executive Officer of Senomyx. "His successful working relationships with external partners will be a valuable asset as Senomyx continues to create new flavor ingredients that meet the needs of our current and potential future collaborators. We welcome the addition of David to Senomyx and look forward to his scientific and managerial contributions to our Discovery & Development programs."
Senomyx's scientific accomplishments have led to the discovery of several new flavor ingredients, including S2383, a novel enhancer of the high intensity sweetener sucralose that is the subject of pre-commercialization activities. In addition, S6973, a sucrose enhancer that enables the reduction of up to 50% of the sugar in food and beverage prototypes, and S0812 and S6821, promising bitter blockers, are undergoing development to support regulatory filings and future commercialization.
About Senomyx, Inc. (www.senomyx.com)
Senomyx is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into product discovery, development, and commercialization collaborations with seven of the world's foremost food, beverage, and ingredient supply companies: Ajinomoto Co., Inc., Cadbury plc, Campbell Soup Company, The Coca-Cola Company, Firmenich SA, Nestle SA, and Solae. Nestle is currently marketing products that contain one of Senomyx's flavor ingredients. For more information, please visit www.senomyx.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Senomyx's ability to discover novel compounds and create new flavor ingredients that are beneficial to our collaborators and Senomyx's ability to successfully complete development activities to support regulatory filings and future commercialization of S6973, S0812, and S6821. Risks that contribute to the uncertain nature of the forward-looking statements include: Senomyx is dependent on its product discovery and development collaborators for all of Senomyx's revenue; Senomyx is dependent on its current and any future product discovery and development collaborators to develop and commercialize any flavor ingredients Senomyx may discover; Senomyx may be unable to develop flavor ingredients useful for formulation into products; the results of development activities for potential flavor ingredients, including safety studies, may not support anticipated regulatory filings; Senomyx or its collaborators may be unable to obtain and maintain the regulatory approval required for flavor ingredients to be incorporated into products that are sold; even if Senomyx or its collaborators receive a regulatory approval and incorporate Senomyx flavor ingredients into products, those products may never be commercially successful; and Senomyx's ability to compete in the flavor ingredients market may decline if Senomyx does not adequately protect its proprietary technologies. These and other risks and uncertainties are described more fully in Senomyx's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risks Related to Our Business" and "Risks Related to Our Industry." All forward-looking statements contained in this press release speak only as of the date on which they were made. Senomyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact: Gwen Rosenberg Senomyx, Inc. Vice President, Investor Relations & Corporate Communications 858-646-8369 email@example.com
|SOURCE Senomyx, Inc.|
Copyright©2009 PR Newswire.
All rights reserved